文献速递先天性心脏病外科瓣膜外科

右心室流出道同种移植物的长期临床结局与超声心动图功能

Long-term clinical outcome and echocardiographic function of homografts in the right ventricular outflow tract†.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

单中心回顾性分析701枚连续植入的右心室流出道同种移植物(604例患者),随访25年生存率84±4%、免于瓣膜置换率56±6%;婴儿期免于置换率最低,成人最高且生活质量与健康人群相当。

要点

  • 25年随访生存率84±4%,免于瓣膜置换率56±6%。
  • 15年免于瓣膜置换率:<1岁28±14%、1–18岁59±8%、>18岁82±5%。
  • 婴儿及儿童峰值压差术后第一个十年从19升至54 mmHg,成人14年后从9升至31 mmHg。

核心结论

  • 同种移植物是右心室流出道重建的耐久瓣膜替代物,尤其成人免于瓣膜置换率高且生活质量与健康受试者相当。

研究设计与样本

  • 单中心回顾性分析连续接受同种移植物行右心室流出道重建的所有患者,同一患者多次植入的同种移植物视为独立对象,共701枚移植物植入604例患者。

主要发现

  • 患者59.6%为男性,手术时平均年龄19.5±15.2岁(标准差),住院死亡率为3.3%。
  • 随访25年后生存率和免于瓣膜置换率分别为84±4%和56±6%。
  • 15年免于瓣膜置换率:<1岁患者28±14%,1–18岁患者59±8%,>18岁患者82±5%。
  • 峰值压差主要在术后第一个十年内增加,婴儿及儿童患者从19升至54 mmHg;成人14年后平均压差从9升至31 mmHg。
  • 与性别和年龄匹配的荷兰人群相比,患者报告活力及总体健康较低但身体疼痛较少;重复评估生活质量的患者在5年随访后躯体功能及活力评分较低,但5年内接受瓣膜置换的患者各亚量表均无差异。

关键数值与推荐

  • 25年生存率84±4%,免于瓣膜置换率56±6%。
  • 15年免于瓣膜置换率:<1岁28±14%,1–18岁59±8%,>18岁82±5%。
  • 婴儿及儿童峰值压差术后第一个十年从19升至54 mmHg;成人14年后平均压差从9升至31 mmHg。

临床怎么用

  • 作者所在机构创建了在线交互式申请表,可用于评估不同患者特征下同种移植物右心室流出道重建后的结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Although homografts are often the preferred valve conduits for right ventricular outflow tract (RVOT) reconstruction, data on long-term homograft-related outcomes, durability and impact on quality of life (QoL) are scarce. The aim of this study was therefore to describe the long-term homograft function, clinical outcomes and QoL after RVOT reconstruction. METHODS: We performed a single-centre retrospective analysis of all consecutive patients who underwent RVOT reconstruction with a homograft. Multiple subsequent allografts in the same patients were regarded as separate subjects. Valve-related events were analysed by Kaplan-Meier and Life Table methods. Serial echocardiographic measurements were analysed with mixed effects models. In addition, QoL was repeatedly assessed and compared with a matched general population. RESULTS: In total, 701 consecutive homografts were implanted in 604 patients [59.6% males, mean age at operation 19.5 ± 15.2 (standard deviation)]. Hospital mortality was 3.3%. After 25 years follow-up, survival and freedom from valve replacement were 84 ± 4% and 56 ± 6%, respectively. Freedom from valve replacement after 15 years for patients under 1 year of age was 28 ± 14% years, for those between 1 and 18 years, 59 ± 8%, and for those older than 18 years, 82 ± 5%. The peak gradient increased predominantly in the first postoperative decade in infants and paediatric patients from 19 to 54 mmHg. In adults, the average gradient increased from 9 to 31 mmHg after 14 years. Compared to a gender- and age-matched Dutch population, patients reported lower vitality and general health but less bodily pain. Patients, in whom QoL was repeatedly assessed, reported lower scores on physical functioning and vitality after a 5-year follow-up period. However, we found no differences in any of the subscales in patients who underwent valve replacement during the 5-year interval. CONCLUSIONS: Homografts are a durable valve alternative for RVOT reconstruction; in particular, adults show extensive freedom from valve replacement and report QoL comparable with healthy subjects. An online interactive application form created by our institution can be used to assess patient outcome after RVOT reconstruction with a homograft for different patient profiles.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Romeo JLR, Mokhles MM, van de Woestijne P, et al. Long-term clinical outcome and echocardiographic function of homografts in the right ventricular outflow tract†. Eur J Cardiothorac Surg. 2019. PMID: 30084965. doi:10.1093/ejcts/ezy265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。